AI Article Synopsis

  • This study observed the health-related quality of life (HRQoL) of 222 moderate to severe Crohn's disease patients in Iran over one year, using various measurement tools including EQ-5D 3L, EQ-VAS, and IBDQ-9.
  • Key factors affecting HRQoL included employment status, the presence of other chronic diseases, and the use of the medication adalimumab (ADA), with unemployment and comorbid conditions identified as major detractors to patients' quality of life.
  • Significant variations in reported problems were found between patients using different medications, specifically ADA and infliximab (IFX), particularly in the dimensions of pain/discomfort (P/D) and anxiety/depression

Article Abstract

This was a 1-year prospective observational study of the health-related quality of life (HRQoL) of moderate to severe crohn's disease (CD) patients in Iran. Patients' HRQoL were measured using the EQ-5D 3L, EQ-VAS, and IBDQ-9 tools. HRQoL among CD patients were compared using the -test, Mann-Whitney, Chi-square, and Fisher's exact tests. To discover factors influencing patients' HRQoL, multivariate linear regression and multivariate logistic regression tests were utilized. The study included 222 CD patients, with a mean age of 34.67 and mean disease duration of 7.32 years. The dimensions with the worst reported "relatively or extreme problems" were P/D: 77.5% and A/D: 63.1%. Employment, having "other chronic diseases," and ADA consumption were the most important independent predictors of HRQoL in CD patients, [β = 0.21 (EQ-5D index), β = 19.61 (EQ-VAS), β = 12.26 (IBDQ-9), OR: 0.09 (MO), OR: 0.12 (UA), OR: 0.21 (P/D), OR: 0.22 (A/D)], [β = -0.15 (EQ-5D index), β = -5.84 (IBDQ-9), β = -11.06 (EQ-VAS), OR: 4.20 (MO), OR: 6.50 (UA)], and [OR: 2.29 (A/D)], respectively. Unemployment, presence of "other chronic conditions" had the greatest negative impact on HRQoL of CD patients. There were significant differences in the probability of reporting "relatively or extreme problems" in the SC and A/D dimensions between patients using adalimumab (ADA) and infliximab (IFX).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907090PMC
http://dx.doi.org/10.3389/fmed.2022.1091330DOI Listing

Publication Analysis

Top Keywords

hrqol patients
12
health-related quality
8
quality life
8
crohn's disease
8
prospective observational
8
observational study
8
patients' hrqol
8
"relatively extreme
8
extreme problems"
8
"other chronic
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!